Background: Here we report a case of complete response in patient with Metastatic Breast Cancer treated by metronomic Chemotherapy. Case presentation: A 51 years old woman underwent righy mastectomy in may 2008. She performed firstline chemotherapy with doxorubicin every 21 days. The CT revaluation after ten cycle showed a partial response to treatment. It was decided to stop the treatment with doxorubicin and to start a metronomic therapy with cyclophosphamide 50 mg daily orally and Methotrexate 2.5 mg twice daily. After two months of this maintenance treatment, the CT scan showed a complete response. The metronomic treatment is still ongoing, and after 45 months the patient maintains a complete response. Conclusion: This clinical case also highlights how suitable metronomic chemotherapy can be as maintenance therapy, allowing long-term treatment with no relevant toxicity.
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy / CASADEI GARDINI, Andrea. - In: JOURNAL OF BLOOD & LYMPH. - ISSN 2165-7831. - 05:(2015), pp. 1-2. [10.4172/2165-7831.1000136]
Complete Response in Patient with Metastatic Breast Cancer Treated with Metronomic Chemotherapy
Andrea, Casadei Gardini
2015-01-01
Abstract
Background: Here we report a case of complete response in patient with Metastatic Breast Cancer treated by metronomic Chemotherapy. Case presentation: A 51 years old woman underwent righy mastectomy in may 2008. She performed firstline chemotherapy with doxorubicin every 21 days. The CT revaluation after ten cycle showed a partial response to treatment. It was decided to stop the treatment with doxorubicin and to start a metronomic therapy with cyclophosphamide 50 mg daily orally and Methotrexate 2.5 mg twice daily. After two months of this maintenance treatment, the CT scan showed a complete response. The metronomic treatment is still ongoing, and after 45 months the patient maintains a complete response. Conclusion: This clinical case also highlights how suitable metronomic chemotherapy can be as maintenance therapy, allowing long-term treatment with no relevant toxicity.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.